Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
Chardan Capital維持對eyepoint pharmaceuticals的買入評級，維持目標價28美元。
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $28 price target.
Chardan Capital分析師Daniil Gataulin維持對eyepoint pharmaceuticals（納斯達克：EYPT）的買入評級，並維持28美元的價格目標。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。